Search results for " FIBRINOGEN"

showing 10 items of 53 documents

D-dimer concentrations in acute urticaria in children

2021

Introduction: Urticaria is a clinical entity presenting as wheals, angioedema, or both simul-taneously. Elevated D-dimer levels were reported in the course of chronic spontaneous urticaria. Data regarding D-dimer levels in acute urticaria in children are limited. Objectives: To assess potential associations between duration of glucocorticosteroid (GCS) therapy and D-dimer concentrations in children with acute urticaria. Patients, materials, and methods: Hospital records of 106 children (59 females), aged 5.57 ± 4.91 years, hospitalized in 2014–2018 were analyzed retrospectively. The study group consisted of pediatric patients admitted to the hospital due to severe acute urticaria resistant …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtypediatricsAdolescentUrticariaImmunologyD-dimersglucocorticosteroidsFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicinechildrenAmbulatory careInternal medicineWhite blood cellD-dimerHumansImmunology and AllergyMedicinePlateletIn patientacute urticariaChildGlucocorticoidsRetrospective StudiesAcute urticariaAngioedemabusiness.industryDisease ManagementInfantGeneral Medicinemedicine.anatomical_structure030228 respiratory systemChild PreschoolAcute DiseaseAntihistaminic drugsFemalemedicine.symptombusinessBiomarkers030215 immunologyAllergologia et Immunopathologia
researchProduct

International, multicenter evaluation of a new D-dimer assay for the exclusion of venous thromboembolism using standard and age-adjusted cut-offs.

2017

We sought to determine the test characteristics of an automated INNOVANCE D-dimer assay for the exclusion of pulmonary embolism (PE) and deep venous thrombosis (DVT) in emergency department (ED) patients using standard and age-adjusted cut-offs.Cross-sectional, international, multicenter study of consecutive patients with suspected DVT or PE in 24 centers (18 USA, 6 Europe). Evaluated patients had low or intermediate Wells PE or DVT scores. For the standard cut-off, a D-dimer result500 ng/ml was negative. For the age adjusted cut-off, we used the formula: Age (years) ∗ 10. The diagnostic standard was imaging demonstrating PE or DVT within 3 months. We calculated test characteristics using s…

Malemedicine.medical_specialtyAge adjustment030204 cardiovascular system & hematologyD-dimer assayFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicinebusiness.industryAge FactorsHematologyEmergency departmentVenous ThromboembolismMiddle Agedmedicine.diseasePulmonary embolismVenous thrombosisCross-Sectional StudiesMulticenter studyDecreased SensitivityBiological AssayFemalebusinessVenous thromboembolismThrombosis research
researchProduct

Genetic and environmental influences on the fibrinolytic system: a twin study.

2004

SummaryThe determination of heritability is a key issue to assess the predictive power of polymorphisms for disease in clinical studies. The aim of this study was to determine the heritability of proteins and activation markers of the fibrinolytic system in a large cohort of healthy twins. Heritability was calculated as 0.76 for thrombin activatable fibrinolysis inhibitor (TAFI), 0.44 for plasminogen activator inhibitor-1 (PAI-1), and 0.43 for tissue plasminogen activator. No significant genetic influence was observed for α2-antiplasmin-plasmin-complex and D-dimer. Heritability explained by single gene polymorphisms was 25.2% for TAFI 505G>A, 31.5% for 1542C>G, and 50.0% for combinati…

Malemedicine.medical_specialtyCarboxypeptidase B2GenotypeArteriosclerosismedicine.medical_treatmentBiologyEnvironmentTissue plasminogen activatorCohort StudiesFibrin Fibrinogen Degradation ProductsInternal medicineFibrinolysisPlasminogen Activator Inhibitor 1medicineDiseases in TwinsHumansFibrinolysinGeneGeneticsalpha-2-AntiplasminPolymorphism GeneticActivator (genetics)FibrinolysisHematologyTwins MonozygoticHeritabilityTwin studyEndocrinologyPhenotypeHaplotypesHemostasisTwin Studies as TopicFemalePlasminogen activatormedicine.drugThrombosis and haemostasis
researchProduct

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsAntithrombin IIIAtrial AppendagePilot Projects030204 cardiovascular system & hematologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanLeft atrialHeart RateInternal medicineAtrial FibrillationMedicineHumansAtrial Appendage030212 general & internal medicineContraindicationBlood CoagulationAgedAppendageAged 80 and overRivaroxabanbusiness.industryDual Anti-Platelet TherapyAtrial fibrillationThrombosisClopidogrelmedicine.diseasePeptide Fragments3. Good healthTreatment OutcomeCardiologyAtrial Function LeftFemaleProthrombinFranceCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsPeptide HydrolasesCirculation. Cardiovascular interventions
researchProduct

Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-Leg Color-Coded Doppler Ultrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis

2008

Context Patients with suspected deep vein thrombosis ( DVT) of the lower extremities are usually investigated with ultrasonography either by the proximal veins ( 2-point ultrasonography) or the entire deep vein system ( whole- leg ultrasonography). The latter approach is thought to be better based on its ability to detect isolated calf vein thrombosis; however, it requires skilled operators and is mainly available only during working hours. No randomized comparisons are yet available evaluating the relative values of these 2 strategies. Objective To assess if the 2 diagnostic strategies are equivalent for the management of symptomatic outpatients with suspected DVT of the lower extremities.…

Malemedicine.medical_specialtyDeep veinContext (language use)VeinsSettore MED/15 - Malattie Del Sanguelaw.inventionFibrin Fibrinogen Degradation ProductsRandomized controlled triallawD-dimermedicineHumansProspective StudiesUltrasonography Doppler ColorProspective cohort studyAgedVenous ThrombosisFirst episodeLegbusiness.industrydeep vein thrombosiultrasonographyGeneral MedicineMiddle Agedmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareThrombosisSurgeryVenous thrombosismedicine.anatomical_structureD-dimerFemaleRadiologybusinessJAMA
researchProduct

Combined lymphocyte/monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility

2020

Abstract Background The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. Here, we retrospectively evaluated and integrated laboratory parameters of 45 elderly subjects from a long-term care facility with Sars-CoV-2 outbreak and spread, to identify potential common patterns of systemic response able to better stratify patients’ clinical course and outcome. Methods Baseline white blood cells, granulocytes’, lymphocytes’, and platelets’ counts, hemoglobin, total iron, ferritin, D-dimer, and interleukin-6 concentration were used to generate a …

Malemedicine.medical_specialtyLymphocyteIronlcsh:MedicineDiseaseMonocyteGeneral Biochemistry Genetics and Molecular BiologyMonocytesFibrin Fibrinogen Degradation ProductsLeukocyte CountLong-term care facilitieInternal medicineD-dimermedicineHumansLymphocytesAgedRetrospective StudiesAged 80 and overbiologybusiness.industryPlatelet CountLong-term care facilitiesClinical outcomeSARS-CoV-2MonocyteResearchlcsh:RCOVID-19Retrospective cohort studyGeneral MedicineBiomarkerMiddle Agedmedicine.diseasePrognosisLong-Term CareFerritinPneumoniamedicine.anatomical_structureTreatment OutcomeD-dimerbiology.proteinFemaleLymphocyteHemoglobinbusinessBiomarkers
researchProduct

Increased plasma concentration of fibrin monomer in acute myocardial infarction with early reperfusion.

1996

OBJECTIVE To assess whether plasma fibrin monomer (FM) concentration, a marker of thrombin activity, is increased in the first hours after acute coronary occlusion and whether there are differences between patients with and without early reperfusion. DESIGN Thirty-five consecutive patients with acute myocardial infarction (AMI) and early coronary angiography were studied prospectively. METHODS Plasma FM samples taken on admission (< 6 h after onset of chest pain) and 6-14 h after onset of chest pain were analysed using a specific enzyme immunoassay. All of the patients were anticoagulated with heparin intravenously. RESULTS Of the 35 patients, 28 had angiographically documented reperfusion …

Malemedicine.medical_specialtyMyocardial InfarctionReference rangeMyocardial ReperfusionChest painCoronary AngiographySensitivity and SpecificityFibrin Fibrinogen Degradation ProductsImmunoenzyme TechniquesTroponin TInternal medicinemedicineHumansMyocardial infarctionProspective StudiesInfusions IntravenousCreatine KinasebiologyTroponin Tbusiness.industryHeparinAnticoagulantsGeneral MedicineHeparinMiddle Agedmedicine.diseaseFibrin MonomerTroponinCoronary occlusionbiology.proteinCardiologyCreatine kinaseFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugCoronary artery disease
researchProduct

D-Dimer and thrombus burden in acute pulmonary embolism.

2018

Abstract Background Thrombus burden in pulmonary embolism (PE) is associated with higher D-Dimer-levels and poorer prognosis. We aimed to investigate i) the influence of right ventricular dysfunction (RVD), deep venous thrombosis (DVT), and high-risk PE-status on D-Dimer-levels and ii) effectiveness of D-Dimer to predict RVD in normotensive PE patients. Methods Overall, 161 PE patients were analyzed retrospectively, classified in 5 subgroups of thrombus burden according to clinical indications and compared regarding D-Dimer-levels. Linear regression models were computed to investigate the association between D-Dimer and the groups. In hemodynamically stable PE patients, a ROC curve was calc…

Malemedicine.medical_specialtyVentricular Dysfunction Right030204 cardiovascular system & hematologyLogistic regressionFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineInternal medicineD-dimerLinear regressionmedicineHumans030212 general & internal medicineAgedRetrospective StudiesVenous Thrombosisbusiness.industryCancerGeneral Medicinemedicine.diseasePrognosisPulmonary embolismVenous thrombosisPneumoniaROC CurveThrombus burdenAcute DiseaseEmergency MedicineCardiologyFemalebusinessPulmonary EmbolismBiomarkersThe American journal of emergency medicine
researchProduct

D-dimer for risk stratification in haemodynamically stable patients with acute pulmonary embolism

2015

Patients with submassive pulmonary embolism (PE) have a higher short-term mortality than those with low-risk PE. Rapid identification of submassive PE is important for adequate treatment of non-massive PE. We aimed to investigate the utility of D-dimer for the prediction of submassive PE stadium in normotensive PE patients.Normotensive PE patients were classified into submassive or low-risk PE groups. In addition to the comparison of the groups, area under the curve (AUC) and D-dimer cut-off for the prediction of submassive PE stadium, multi-variate logistic regression for association between D-dimer values above this cut-off and submassive PE stadium were also calculated.The data of 129 no…

Malemedicine.medical_specialtyVentricular Dysfunction RightFibrin Fibrinogen Degradation ProductsTachycardiaInternal medicineHeart rateD-dimerHumansMedicineIn patientAgedRetrospective StudiesAged 80 and overbusiness.industryArea under the curveGeneral MedicineMiddle Agedmedicine.diseasePulmonary embolismLogistic ModelsBlood pressureHaemodynamically stableRisk stratificationCardiologyFemalePulmonary EmbolismbusinessAdvances in Medical Sciences
researchProduct

The control of anti-coagulation in acute dialyses with sensitive laboratory parameters.

1992

In seven patients who had to be dialysed between four and 13 times due to acute renal failure, low molecular weight heparin (LMWH) Fragmin was used for anticoagulation. According to dose-finding studies, 80-90 U kg-1 body weight of LMWH as a single bolus were administered initially, producing dose-related levels of 0.3-1.5 anti-factor Xa U ml-1 in plasma. Apart from the anti-Xa activity in the plasma, the thrombin anti-thrombin III complex (TAT complex) and a fibrin degradation product (D-dimer) were measured as parameters of a coagulation activation. A sufficient anti-coagulation during dialysis was supposed to exist at a normal range (5.0 micrograms l-1 or below) of TAT complex. Pathologi…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentClinical BiochemistryAntithrombin IIILow molecular weight heparinPharmacologyFibrin Fibrinogen Degradation ProductsThrombinRenal DialysisD-dimermedicineHumansBlood CoagulationDialysisAgedFibrin degradation productbusiness.industryAnticoagulantExtracorporeal circulationAnticoagulantsGeneral MedicineHeparinAcute Kidney InjuryHeparin Low-Molecular-WeightMiddle AgedSurgerybusinessmedicine.drugFactor Xa InhibitorsPeptide HydrolasesScandinavian journal of clinical and laboratory investigation
researchProduct